Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces boulardii to prevent antibiotic-associated diarrhea in young children
ChiCTR2600118549Phase 4Not yet recruiting
- Sponsor
- Shenzhen Children's Hospital
- Start
- Feb 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of saccharomyces boulardii in antibiotic-associated diarrhea (AAD) and diarrhea (2 arms), sponsored by Shenzhen Children's Hospital. Primary endpoint: Incidence of Pediatric Antibiotic-Associated Diarrhea. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
saccharomyces boulardii
03
Conditions
antibiotic-associated diarrhea (AAD)diarrhea
Beyond the preview
Go deeper on ChiCTR2600118549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118549.